QQQ   328.59 (+0.15%)
AAPL   143.16 (+0.17%)
MSFT   232.33 (+1.22%)
FB   282.05 (+1.45%)
GOOGL   1,907.95 (+0.72%)
AMZN   3,326.13 (+0.98%)
TSLA   883.09 (+0.26%)
NVDA   537.41 (-1.60%)
BABA   265.92 (+1.74%)
CGC   35.52 (+7.93%)
GE   11.29 (+2.73%)
MU   79.51 (-2.18%)
AMD   94.71 (+0.62%)
NIO   60.31 (+0.53%)
T   29.75 (+2.20%)
F   11.19 (-0.89%)
ACB   10.67 (+5.02%)
BA   202.06 (-0.64%)
DIS   169.56 (-1.36%)
NFLX   561.93 (+0.92%)
GILD   66.70 (-2.14%)
QQQ   328.59 (+0.15%)
AAPL   143.16 (+0.17%)
MSFT   232.33 (+1.22%)
FB   282.05 (+1.45%)
GOOGL   1,907.95 (+0.72%)
AMZN   3,326.13 (+0.98%)
TSLA   883.09 (+0.26%)
NVDA   537.41 (-1.60%)
BABA   265.92 (+1.74%)
CGC   35.52 (+7.93%)
GE   11.29 (+2.73%)
MU   79.51 (-2.18%)
AMD   94.71 (+0.62%)
NIO   60.31 (+0.53%)
T   29.75 (+2.20%)
F   11.19 (-0.89%)
ACB   10.67 (+5.02%)
BA   202.06 (-0.64%)
DIS   169.56 (-1.36%)
NFLX   561.93 (+0.92%)
GILD   66.70 (-2.14%)
QQQ   328.59 (+0.15%)
AAPL   143.16 (+0.17%)
MSFT   232.33 (+1.22%)
FB   282.05 (+1.45%)
GOOGL   1,907.95 (+0.72%)
AMZN   3,326.13 (+0.98%)
TSLA   883.09 (+0.26%)
NVDA   537.41 (-1.60%)
BABA   265.92 (+1.74%)
CGC   35.52 (+7.93%)
GE   11.29 (+2.73%)
MU   79.51 (-2.18%)
AMD   94.71 (+0.62%)
NIO   60.31 (+0.53%)
T   29.75 (+2.20%)
F   11.19 (-0.89%)
ACB   10.67 (+5.02%)
BA   202.06 (-0.64%)
DIS   169.56 (-1.36%)
NFLX   561.93 (+0.92%)
GILD   66.70 (-2.14%)
QQQ   328.59 (+0.15%)
AAPL   143.16 (+0.17%)
MSFT   232.33 (+1.22%)
FB   282.05 (+1.45%)
GOOGL   1,907.95 (+0.72%)
AMZN   3,326.13 (+0.98%)
TSLA   883.09 (+0.26%)
NVDA   537.41 (-1.60%)
BABA   265.92 (+1.74%)
CGC   35.52 (+7.93%)
GE   11.29 (+2.73%)
MU   79.51 (-2.18%)
AMD   94.71 (+0.62%)
NIO   60.31 (+0.53%)
T   29.75 (+2.20%)
F   11.19 (-0.89%)
ACB   10.67 (+5.02%)
BA   202.06 (-0.64%)
DIS   169.56 (-1.36%)
NFLX   561.93 (+0.92%)
GILD   66.70 (-2.14%)
Log in
NASDAQ:FENC

Fennec Pharmaceuticals Stock Forecast, Price & News

$7.68
-0.41 (-5.07 %)
(As of 01/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.57
Now: $7.68
$8.07
50-Day Range
$7.09
MA: $7.52
$8.19
52-Week Range
$4.65
Now: $7.68
$10.67
Volume114,343 shs
Average Volume80,559 shs
Market Capitalization$198.22 million
P/E RatioN/A
Dividend YieldN/A
Beta0.07
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Fennec Pharmaceuticals logo

MarketRank

Overall MarketRank

1.49 out of 5 stars

Medical Sector

430th out of 1,925 stocks

Biological Products, Except Diagnostic Industry

56th out of 177 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FENC
CUSIPN/A
Phone919-636-4530
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.60 per share

Profitability

Net Income$-12,770,000.00

Miscellaneous

Market Cap$198.22 million
Next Earnings Date2/12/2021 (Estimated)
OptionableOptionable
$7.68
-0.41 (-5.07 %)
(As of 01/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FENC News and Ratings via Email

Sign-up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Fennec Pharmaceuticals (NASDAQ:FENC) Frequently Asked Questions

How has Fennec Pharmaceuticals' stock price been impacted by Coronavirus?

Fennec Pharmaceuticals' stock was trading at $6.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, FENC shares have increased by 15.8% and is now trading at $7.68.
View which stocks have been most impacted by COVID-19
.

Is Fennec Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Fennec Pharmaceuticals stock.
View analyst ratings for Fennec Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Fennec Pharmaceuticals?

Wall Street analysts have given Fennec Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Fennec Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Fennec Pharmaceuticals' next earnings date?

Fennec Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, February 12th 2021.
View our earnings forecast for Fennec Pharmaceuticals
.

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc (NASDAQ:FENC) posted its quarterly earnings results on Sunday, November, 15th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.05.
View Fennec Pharmaceuticals' earnings history
.

What price target have analysts set for FENC?

3 equities research analysts have issued 1-year target prices for Fennec Pharmaceuticals' shares. Their forecasts range from $11.00 to $18.00. On average, they expect Fennec Pharmaceuticals' stock price to reach $14.67 in the next twelve months. This suggests a possible upside of 91.0% from the stock's current price.
View analysts' price targets for Fennec Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of Fennec Pharmaceuticals' key competitors?

What other stocks do shareholders of Fennec Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus BioSciences (CHRS) and Exelixis (EXEL).

Who are Fennec Pharmaceuticals' key executives?

Fennec Pharmaceuticals' management team includes the following people:
  • Mr. Rostislav Raykov, Pres, CEO & Director (Age 42)
  • Mr. Robert C. Andrade, Chief Financial Officer (Age 43)
  • Mr. Mark Gowland, Controller
  • Mr. Lei Fang, Pres of Pharstat Inc
  • Ms. Anne McKay, Regulatory Consultant (Age 64)

What is Fennec Pharmaceuticals' stock symbol?

Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."

How do I buy shares of Fennec Pharmaceuticals?

Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Fennec Pharmaceuticals' stock price today?

One share of FENC stock can currently be purchased for approximately $7.68.

How big of a company is Fennec Pharmaceuticals?

Fennec Pharmaceuticals has a market capitalization of $198.22 million. The company earns $-12,770,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis.

What is Fennec Pharmaceuticals' official website?

The official website for Fennec Pharmaceuticals is www.fennecpharma.com.

How can I contact Fennec Pharmaceuticals?

Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530.

This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.